Septerna, Inc. (NASDAQ:SEPN) Director Buys $47,567.85 in Stock

Septerna, Inc. (NASDAQ:SEPN) Director Alan Ezekowitz purchased 7,491 shares of the company’s stock in a transaction dated Tuesday, March 4th. The shares were acquired at an average price of $6.35 per share, for a total transaction of $47,567.85. Following the purchase, the director now directly owns 24,911 shares of the company’s stock, valued at approximately $158,184.85. The trade was a 43.00 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link.

Alan Ezekowitz also recently made the following trade(s):

• On Thursday, March 6th, Alan Ezekowitz purchased 41,355 shares of Septerna stock. The shares were acquired at an average price of $6.00 per share, for a total transaction of $248,130.00.

Septerna Stock Performance

Shares of NASDAQ SEPN opened at $6.43 on Friday. The firm has a 50 day moving average price of $14.10. Septerna, Inc. has a 52 week low of $4.17 and a 52 week high of $28.99.

Institutional Investors Weigh In On Septerna

A number of large investors have recently bought and sold shares of SEPN. SG Americas Securities LLC purchased a new stake in Septerna in the 4th quarter worth approximately $185,000. Rhumbline Advisers purchased a new stake in Septerna in the 4th quarter worth approximately $458,000. New York State Common Retirement Fund purchased a new stake in Septerna in the 4th quarter worth approximately $32,000. Bank of New York Mellon Corp purchased a new stake in Septerna in the 4th quarter worth approximately $872,000. Finally, Charles Schwab Investment Management Inc. purchased a new stake in Septerna in the 4th quarter worth approximately $3,197,000.

Analyst Upgrades and Downgrades

SEPN has been the topic of a number of research analyst reports. Wells Fargo & Company lowered Septerna from an “overweight” rating to an “equal weight” rating and dropped their price target for the stock from $43.00 to $14.00 in a research note on Tuesday, February 18th. Cantor Fitzgerald restated an “overweight” rating and set a $50.00 price target on shares of Septerna in a research note on Tuesday, February 11th. JPMorgan Chase & Co. assumed coverage on Septerna in a research report on Tuesday, November 19th. They issued an “overweight” rating and a $38.00 target price on the stock. Finally, TD Cowen assumed coverage on Septerna in a research report on Tuesday, November 19th. They issued a “buy” rating on the stock.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.